BioSpace News Archive

Zentalis® Pharmaceuticals, Inc. announced that on February 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 451,250 shares of the Company’s common stock and 165,000 restricted stock units to six newly hired employees.

Ligand Pharmaceuticals Incorporated announced that effective February 1, 2024, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 93,700 shares of its common stock, 32,750 restricted stock units and 40,000 performance stock units to two non-executive employees.

BioVaxys Technology Corp. announces that it has completed the first tranche of a non-brokered private placement consisting of 36,783,334 at a price of $0.03 per Unit for total gross proceeds of $1,103,500.

Domrex Pharma Inc., a leading manufacturer and distributor of medical supplies in Canada, is thrilled to announce the acceleration of its expansion into the United States.

Tyra Biosciences, Inc. (Nasdaq: TYRA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia.

Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has received clearance from the U.S. Food and Drug Administration (FDA), making it the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share.

Fractyl Health announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health.

Shanghai Junshi Biosciences Co., Ltd announced that the Singapore Health Sciences Authority had accepted the New Drug Application for toripalimab, both in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI, for the prevention and treatment of thromboembolic disorders.